SpringWorks Therapeutics, a biopharmaceutical company that specializes in developing life-changing medicines for individuals with severe rare diseases and cancer, announced that their management will participate in a fireside chat at the BofA Securities 2024 Health Care Conference in Las Vegas on May 14, 2024. The webcast of the chat can be accessed on the company’s website and a replay will be available for a limited time after the event.
SpringWorks Therapeutics has been making significant strides in recent years, with a diversified targeted oncology pipeline and clinical trials underway in rare tumor types and genetically defined cancers. Their FDA-approved therapy, OGSIVEO®, is currently being used to treat adult patients with desmoid tumors.
Founded in 2017, SpringWorks Therapeutics has quickly progressed their lead product candidates into late-stage trials and established collaborations with industry innovators and academia. This strategic approach, combined with operational excellence, has enabled them to create more solutions for cancer patients and unlock the full potential of their portfolio.
For more information about SpringWorks Therapeutics, visit their website and follow them on social media platforms. Contact Kim Diamond, Vice President of Communications and Investor Relations or Samantha Hilson Sandler, Senior Director of Investor Relations for further inquiries.